Phase 2 N=5 Clostridium Histolyticum Collagenase Injection for Urethral Disease
Urethral Stricture
Primary: Number of Subjects With Complication After Treatment — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=101 Prostatic Urethral Lift in Subject With Acute Urinary Retention
Acute Urinary Retention · Benign Prostatic Hyperplasia
Primary: Successful Trial Without Catheter Peri-procedurally — 29; 0 Participants
N/A N=107 Use of The Spanner Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men
Urinary Retention
Primary: Number of Participants Who Achieved Post-void Residual (PVR) of ≤150 ml Over 90 Days — 79 Participants
N/A N=24 The RELIEF™ Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position
Ureteral Obstruction
Primary: Incidence of Bladder Irritation Symptoms (e.g. Frequency, Urgency, Nocturia, Urine Leakage...) Associated With the RELIEF Stent. — 51.95 Units on a scale
N/A N=45 Study of Median Lobe Prostatic UroLift Procedure
Benign Prostatic Hyperplasia (BPH)
Primary: At 6 Months, the 95% Lower Confidence Limit of the Mean Percent Improvement in IPSS Over Baseline for the UroLift System Must be ≥ 25%. — 57.7 percent change
N/A N=130 Ureteroscope Caliber and Surgeon Stress
Ureteral Stones · Ureteroscopic Lithotripsy
Primary: Change in STAI-TX1 Score (Postoperative - Preoperative) — 1.35; 5.05 Scores on a scale
Phase 3 N=37 Bladder Scan of Residual Urine With New Catheter
Urinary Incontinence
Primary: Mean Residual Urine Volume — 12.4; 9.4 mL
N/A N=24 Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent
Ureteral Obstruction
Primary: Mean Stent Dwell Time — 17; 3.97 months
N/A N=95 Impact Ureteral Sheath Design During Ureteroscopy
Renal Stone · Nephrolithiasis · Urolithiasis
Primary: Number of Participants With Successful Sheath Placement — 37; 39 Participants
Phase 4 N=232 The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients
BPH
Primary: Primary Outcome; International Prostate Symptom Score Changes Between 4 Groups Compared to Baseline After 12 mo Treatment — 13.0; 12.0; 10.6; 13.4 score — p=<0.05
N/A N=45 BULLET: Bladder Ultrasound Limits Length (of Time), Expedites Treatment
Point-of-Care Bladder Ultrasound · Urethral Catheter
Primary: Time to Successful Completion of Pelvic Ultrasound — 103.95; 92.82 minutes
N/A N=56 Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters
Urethral Sphincter Activity
Primary: Difference (Pre - Post) in Amplitude (Microvolts) of Urethral Sphincter Activity as Measured by Quantitative Concentric Needle EMG — -18; 10; 11; -15 microvolts — p=>0.05
N/A N=12 Urodynamic Feasibility Study Utilizing the UroLift® System
Benign Prostatic Hyperplasia
Primary: Qmax Assessed Using Urodynamic Testing (Cystometry) — 14.0 mL/sec
N/A N=23 Effect of Urethral Analgesia on Voiding
Urethral Analgesia
Primary: Voiding Efficiency — 87; 90 Percent voiding efficiency
N/A N=18 WallFlex Esophageal Fully Covered (FC) Benign Anastomotic Stricture
Refractory Anastomotic Esophageal Strictures
Primary: Number of Dilation Procedures — 5.4; 2.4 Dilation procedures — p=0.159
Phase 4 N=63 Lessons on Urethral Lidocaine in Urodynamics
Urethra Issue · Pelvic Organ Prolapse · Urinary Incontinence
Primary: Sensation as Indicated by the Volume of Water Filled (ml) at the Time of Patient Perception of First Sensation, First Urge to Void, Strong Urge to Void, and Full Bladder…
Phase 4 N=181 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction
Ureteral Obstruction
Primary: Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion — 1.76; 1.84; 2.02; 1.93 score on a scale
Phase 2 N=25 Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery
Urinary Incontinence · Stress · Urination Disorders
Primary: Rate of Product-related, Biopsy Procedure-related, and Injection Procedure-related Adverse Events — 0; 2; 0; 12 events
N/A N=150 Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Urinary Incontinence · Prostate Cancer
Primary: Number of Continent Patients Post Prostatectomy — 37; 32 participants
N/A N=124 ProACT Therapy for the Treatment of Stress Urinary Incontinence in Males
Urinary Incontinence
Primary: Primary Efficacy: Demonstrate the Efficacy of the ProACT Device in Reducing Incontinence as Measured by the 24-hour Pad Weight at 18 Months Compared to Baseline. A…
N/A N=108 Occlusion Balloon vs. 5FR Ureteral Catheter
Kidney Stones
Primary: Number of Participants With Ureteral Stone Fragments Identified Endoscopically — 2; 8 Participants
N/A N=67 Antibiotic Use Following Distal and Mid-shaft Hypospadias Repair
Hypospadias
Primary: Number of Participants With Urinary Tract Infection — 30; 22; 0; 0 Participants
Phase 3 N=104 The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
Disorder of Urinary Stent
Primary: Lower Urinary Tract Symptoms (LUTS) — 11.12; 4.39; 7.21; 5.58 units on a scale
Phase 3 N=655 Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence
Urinary Incontinence
Primary: 24 Month Cumulative Success Rate Computed From Kaplan Meier Time-to-event Analysis (Reported as Percent Success). — 38; 47 % success at 24 months — p=0.01
N/A N=36 A Randomized Controlled Trial of the Uresta Continence Pessary
Stress Urinary Incontinence
Primary: A 50% Reduction in Pad Test Weight — 12; 4 Participants
Phase 1 N=3 Two Devices for Reflex Voiding Following Spinal Cord Injury
Spinal Cord Injury · Urinary Incontinence
Primary: Number of Participants With a Change in Bladder Pressure — 0 participants
N/A N=26 Outcomes of Esophageal Self Dilation for Benign Refractory Esophageal Stricture Management
Esophageal Dilation · Refractory Benign Esophageal Stricture
Primary: Number of Endoscopic Interventions — 12; 11; 12; 7 endoscopies
Phase 3 N=187 WallFlex Biliary Fully Covered (FC) Benign Stricture Study
Biliary Stricture
Primary: Stent Removability — 132 Participants
Early Phase 1 N=53 ROBUST I Pilot Study, Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease
Stricture Urethra
Primary: Rate of Treatment Related Serious Complication — 0 percentage of participants
Phase 4 N=77 Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract Symptoms
Flank Pain · Urinary Bladder, Overactive
Primary: Change in Post-ureteroscopy Stent-induced Pain — 4.61; 3.11 units on a scale